Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern.
Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern.
复制标题
DOI：
10.1038/s41564-021-00974-0
复制
发表时间：
2021-11
影响因子：
28.3
通讯作者：
Doores KJ
中科院分区：
文献类型：
--
作者：
Dupont L;Snell LB;Graham C;Seow J;Merrick B;Lechmere T;Maguire TJA;Hallett SR;Pickering S;Charalampous T;Alcolea-Medina A;Huettner I;Jimenez-Guardeño JM;Acors S;Almeida N;Cox D;Dickenson RE;Galao RP;Kouphou N;Lista MJ;Ortega-Prieto AM;Wilson H;Winstone H;Fairhead C;Su JZ;Nebbia G;Batra R;Neil S;Shankar-Hari M;Edgeworth JD;Malim MH;Doores KJ
COVID-19疫苗设计和疫苗接种需要详细了解抗体耐久性和针对SARS-CoV-2和新出现的关注变体（VOCs）的交叉中和潜力。对恢复期血清的分析提供了对变异刺突蛋白诱导的抗体寿命和交叉中和活性的独特见解，这是假定的候选疫苗。利用38名第1波感染者的血清，我们发现交叉中和活性可以在症状出现后305天检测到，尽管血清对B.1.1.7 （α）和B1.351 （β）的效力较弱。随着时间的推移，尽管总体中和活性降低，但血清对SARS-CoV-2和α和β变体的中和效力差异减小，这表明抗体的持续成熟提高了对刺突突变的耐受性。我们还比较了波1血清与感染α、β或B.1.617.2 （Delta）变体的个体血清在症状出现后79天内的交叉中和活性。虽然这些血清将感染VOC和亲本病毒中和到相似的水平，但不同SARS-CoV-2 VOC谱系的交叉中和减少。这些发现将为优化针对SARS-CoV-2变体的疫苗提供信息。作者评估了为应对SARS-CoV-2感染或人类关注的变体而产生的中和抗体的持久性和长期交叉反应性。
COVID-19 vaccine design and vaccination rollout need to take into account a detailed understanding of antibody durability and cross-neutralizing potential against SARS-CoV-2 and emerging variants of concern (VOCs). Analyses of convalescent sera provide unique insights into antibody longevity and cross-neutralizing activity induced by variant spike proteins, which are putative vaccine candidates. Using sera from 38 individuals infected in wave 1, we show that cross-neutralizing activity can be detected up to 305 days pos onset of symptoms, although sera were less potent against B.1.1.7 (Alpha) and B1.351 (Beta). Over time, despite a reduction in overall neutralization activity, differences in sera neutralization potency against SARS-CoV-2 and the Alpha and Beta variants decreased, which suggests that continued antibody maturation improves tolerance to spike mutations. We also compared the cross-neutralizing activity of wave 1 sera with sera from individuals infected with the Alpha, the Beta or the B.1.617.2 (Delta) variants up to 79 days post onset of symptoms. While these sera neutralize the infecting VOC and parental virus to similar levels, cross-neutralization of different SARS-CoV-2 VOC lineages is reduced. These findings will inform the optimization of vaccines to protect against SARS-CoV-2 variants. The authors assess the durability and long-term cross-reactivity of neutralizing antibodies raised in response to infections with SARS-CoV-2 or variants of concern in humans.
登录
查看更多内容
DOI：
10.1016/j.xcrm.2021.100290
发表时间：
2021-06-15
期刊：
Cell reports. Medicine
影响因子：
--
作者：
Anand SP;Prévost J;Nayrac M;Beaudoin-Bussières G;Benlarbi M;Gasser R;Brassard N;Laumaea A;Gong SY;Bourassa C;Brunet-Ratnasingham E;Medjahed H;Gendron-Lepage G;Goyette G;Gokool L;Morrisseau C;Bégin P;Martel-Laferrière V;Tremblay C;Richard J;Bazin R;Duerr R;Kaufmann DE;Finzi A
通讯作者：
Finzi A
影响因子：
9.4
作者：
Addetia A;Crawford KHD;Dingens A;Zhu H;Roychoudhury P;Huang ML;Jerome KR;Bloom JD;Greninger AL
通讯作者：
Greninger AL
DOI：
10.1038/s41577-021-00522-1
发表时间：
2021-04
期刊：
Nature reviews. Immunology
影响因子：
--
作者：
Carvalho T;Krammer F;Iwasaki A
通讯作者：
Iwasaki A
DOI：
10.1101/2020.06.15.153387
发表时间：
2021-01-01
期刊：
JACC. Basic to translational science
影响因子：
--
作者：
Beddingfield, Brandon J;Iwanaga, Naoki;Bix, Gregory J
通讯作者：
Bix, Gregory J
整合素结合肽 ATN-161，作为 SARS-CoV-2 感染的新疗法。
DOI：
10.1016/j.jacbts.2020.10.003
发表时间：
2021-01
期刊：
JACC. Basic to translational science
影响因子：
--
作者：
Beddingfield BJ;Iwanaga N;Chapagain PP;Zheng W;Roy CJ;Hu TY;Kolls JK;Bix GJ
通讯作者：
Bix GJ